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Insulin-like growth factor I (IGF-I) is a key regulator of muscle development and growth.
The pre-pro-peptide produced by the Igf1 gene undergoes several post-translational pro-
cessing steps to result in a secreted mature protein, which is thought to be the obligate
ligand for the IGF-I receptor (IGF-IR). However, the significance of the additional forms and
peptides produced from Igf1 is not clear. For instance, the C-terminal extensions called the
E-peptides that are part of pro-IGF-I, have been implicated in playing roles in cell growth,
including cell proliferation and migration and muscle hypertrophy in an IGF-IR independent
manner. However, the activity of these peptides has been controversial. IGF-IR indepen-
dent actions suggest the existence of an E-peptide receptor, yet such a protein has not
been discovered. We propose a new concept: there is no E-peptide receptor, rather the E-
peptides coordinate with IGF-I to modulate activity of the IGF-IR. Growing evidence reveals
that the presence of an E-peptide alters IGF-I activity, whether as part of pro-IGF-I, or as a
separate peptide. In this review, we will examine the past literature on IGF-I processing and
E-peptide actions in skeletal muscle, address the previous attempts to separate IGF-I and
E-peptide effects, propose a new model for IGF-I/E-peptide synergy, and suggest future
experiments to test if the E-peptides truly modulate IGF-I activity.
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IGF-I REGULATES SKELETAL MUSCLE GROWTH AND REPAIR
Insulin-like growth factor I (IGF-I) has endocrine and
autocrine/paracrine activities that regulate pre- and postnatal
growth in many tissues. The main source of IGF-I is the liver
(Schwander et al., 1983), which secretes IGF-I into the circulation.
However, many cell types, including skeletal muscle, produce, and
respond to IGF-I. IGF-I promotes growth via binding to and acti-
vating its transmembrane tyrosine kinase receptor, IGF-I Receptor
(IGF-IR). Upon IGF-I binding, the IGF-IR cytoplasmic domain is
autophosphorylated, which initiates multiple signaling cascades
and leads to increased growth, protein synthesis, and survival.
The IGF-I pathway is an essential component of growth and
repair in mature skeletal muscle. Since muscle fibers are post-
mitotic, growth and regeneration rely on a stem cell-like niche of
quiescent pre-muscle cells called satellite cells (Mauro,1961). Once
activated by signals for growth, overload, or injury, satellite cells
proliferate, migrate to the region of the muscle that requires extra
nuclei, and differentiate by fusing with myofibers (Florini et al.,
1996). IGF-I is involved in many of these steps, such as myoblast
proliferation and differentiation (Quinn et al., 1994; Quinn and
Haugk, 1996). These processes are mediated through IGF-IR
downstream pathways (Philippou et al., 2007). The mitogen-
activated protein kinase (MAPK) pathway, which includes extra-
cellular signal-regulated kinase 1 and 2 (ERK1/2), increases pro-
liferation and migration in satellite cells and myoblasts. The
phosphoinositide 3-kinase (PI3K/Akt) pathway is also stimulated,
which increases differentiation and protein synthesis in mature
muscle fibers (Johnson and Allen, 1990; Coolican et al., 1997;
Leloup et al., 2007).
The necessity of IGF-I activity for muscle growth and repair was
established through several animal models. For instance, IGF-IR
inactivation in skeletal muscle leads to 10–30% lower mass (Fer-
nandez et al., 2002; Mavalli et al., 2010) and delayed regeneration
after injury (Heron-Milhavet et al., 2010). Accordingly, one can
also enhance growth processes by increasing IGF-I, by infusion of
recombinant IGF-I (Adams and McCue, 1998), transgenic muscle-
specific over-expression (Coleman et al., 1995; Musaro et al., 2001),
or viral gene delivery (Barton-Davis et al., 1998). These strategies
cause hypertrophy, improve diseased muscle phenotype and func-
tion (Lynch et al., 2001; Barton et al., 2002), accelerate regeneration
after injury (Rabinovsky et al., 2003; Schertzer and Lynch, 2006),
and enhance hypertrophy in response to resistance training (Lee
et al., 2004). Thus, there is great interest in therapeutic use of IGF-I
for driving muscle growth.
IGF-I PROTEIN PROCESSING
The general consensus is that all IGF-I activity is mediated by
mature IGF-I, but the Igf1 gene encodes more than this protein.
In the early 1980s, it was proposed that IGF-I was synthesized as
a precursor protein requiring proteolysis at both the N- and C-
termini to produce mature IGF-I (Jansen et al., 1983). Mature
IGF-I consists of 70 amino acids (Rinderknecht and Humbel,
1978), but the full-length precursor, pre-pro-IGF-I, contains a
signal peptide, mature IGF-I, and a C-terminal E-peptide exten-
sion (Figure 1). The N-terminal signal peptide is cleaved during
translation in the ER, resulting in Pro-IGF-I. The E-peptide is so
named because it follows the B-C-A-D domains of mature IGF-I,
like the domains of insulin (Steiner, 1969). The E-peptide begins
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FIGURE 1 | Insulin-like growth factor I processing leading to mature
IGF-I.The Igf1 gene is first translated into a Pre-pro-IGF-I precursor protein
that includes a signal peptide, signal peptide cleavage site, IGF-I, pro-protein
convertase cleavage site, and E-peptide. During translation, the signal peptide
is removed from the remaining protein, now called Pro-IGF-I. Further protease
cleavage separates the mature IGF-I from free E-peptide. While mature IGF-I
has many accepted growth effects on a wide variety of cells and tissues, the
purpose and actions of the E-peptides are relatively unknown.
at amino acid 71, which is in a unique pentabasic prohormone
cleavage motif Lys-X-X-Lys-Arg71-X-X-Arg-X-X-Arg77 (Duguay
et al., 1995). Subtilisin-related proprotein convertases like furin
can cleave polypeptides that include this motif, resulting in free
mature IGF-I and an E-peptide (Duguay et al., 1995, 1997; Duguay,
1999). Intriguingly, uncleaved pro-IGF-I is detectable in condi-
tioned media and in vivo in serum (Powell et al., 1987; Conover
et al., 1989, 1993; Wilson et al., 2001; Barton et al., 2012; Durzynska
et al., 2013a). To date, however, it is unclear if pro-IGF-I is bioac-
tive or simply an inactive precursor or source for mature IGF-I
and/or E-peptides.
The complexity of Igf1 is heightened by extensive alternative
splicing. The critical splicing events that determine which pro-
IGF-I isoform is expressed occur at the 3′ end of the Igf1 gene,
but all isoforms retain an invariant mature IGF-I sequence. In
rodents and other non-primate mammals, there are two Igf1 iso-
forms called IGF-IA (IA) and IGF-IB (IB), containing E-peptides
A and B (EA and EB, respectively). In humans, there are three
possible isoforms: A, B, and C, where the B form is unique to
humans (reviewed in Barton, 2006a). In all species, the predomi-
nant IGF-I isoform produced is IA, which is the most conserved
across all species examined (Shimatsu and Rotwein, 1987; Lowe
et al., 1988; Shamblott and Chen, 1993; Lund, 1998; Wallis, 2009).
For an extensive discussion on IGF-I splicing, please (see Tahimic
et al., 2013) in this Frontiers Research Topic.
A second facet of complexity results from glycosylation of IGF-
IA. Rodent EA has two potential N-glycosylation sites, and human
EA has one (Bach et al., 1990). In a recent study, we saw that
IGF-I in skeletal muscle was predominantly glycosylated pro-IGF-
I (Durzynska et al., 2013a), suggesting that there is a biological
purpose for glycosylation on EA. Many extracellular proteins are
glycosylated and interact with the extracellular matrix (ECM), and
so EA glycosylation could provide IGF-I storage in the ECM for
subsequent activity by cleavage (Jansen et al., 1983). However,
the extent of glycosylation or cleavage may vary across differ-
ent cell types. Thus, it is possible that retaining EA is a way to
keep IGF-I within the muscle tissue, potentially attached to the
ECM. Taken together, the conservation of alternative splicing and
glycosylation suggest a physiological reason for retaining these
processes. We propose that there are multiple active forms of IGF-I,
and that processing provides means for altering IGF-I potency,
stabilization, and/or storage.
SEARCHING FOR E-PEPTIDE BIOLOGICAL ACTIVITY: A
HISTORY
Since only the E-peptides differ between IGF-I isoforms, it was
suggested that the E-peptides themselves had activity (Shimatsu
and Rotwein, 1987). Initial studies focused on the unique human
E-peptide, hEB (Siegfried et al., 1992), and found increased pro-
liferation in human bronchial epithelial cells with hEB exposure.
When a neutralizing antibody to IGF-IR was added to the prolif-
eration assay, hEB could still induce proliferation, suggesting that
hEB does not act through IGF-IR. Years later, it was discovered
that hEB localizes to nucleoli (Tan et al., 2002), induces neuroblas-
toma cell differentiation, and increases neurite growth and ERK1/2
phosphorylation (Kuo and Chen, 2002). Recent data from our
lab shows that full-length hEB increases proliferation and migra-
tion in multiple human cell lines (Durzynska et al., 2013b). Thus,
the first E-peptide studied did have biological activity presumably
independent from IGF-I actions.
Additional evidence for active E-peptides originates from stud-
ies of rainbow trout,Oncorhynchus mykiss, where there are four E-
peptides (Ea-1, Ea-2, Ea-3, and Ea-4) homologous to mammalian
EA (Shamblott and Chen, 1993). Recombinant Ea-2, -3, and -4
increase proliferation in mouse fibroblasts, transformed human
embryonic kidney cells, and human mammary gland tumor cells
(Tian et al., 1999), supporting cross-species conservation of activ-
ity. In addition, Ea-2 and -4 diminish cancer colony formation,
enhanced cell attachment, and reduce invasive activity similar to
hEB (Chen et al., 2002). These studies added to the hypothesis
that there is biological significance for the E-peptides in the Igf1
gene.
Focus on the IB/hIC isoform, specifically in skeletal muscle,
began in the late 1990s, when the Goldspink laboratory found that
while resting muscle expressed only IA, stretched rabbit muscles
undergoing hypertrophy expressed both IA and IB (Yang et al.,
1996). The group postulated that the IB isoform was responsi-
ble for the stretch induced hypertrophy, and renamed it Mechano
Growth Factor (MGF) to distinguish it from the liver forms of IGF-
I. After muscle injury, there was a transient increase in IB/MGF
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expression which occurred just prior to the activation of satellite
cells (Hill and Goldspink, 2003; Hill et al., 2003). The temporal
expression of IB/MGF led to an attractive hypothesis that this
isoform, or more specifically the EB/hEC peptide, was respon-
sible for activating satellite cells, leading to muscle hypertrophy.
Consistent with this, the group showed the IB/MGF response
diminished with age, where there is limited satellite cell activa-
tion (Owino et al., 2001; Hameed et al., 2003). Given the interest
of the lay muscle community in factors that can drive muscle
growth, MGF took on a life of its own, even though there was
limited substantial, peer-reviewed evidence for its potency. Ulti-
mately, several groups have demonstrated that synthetic MGF
(corresponding to the last 24 or 25 amino acids of the IB/hIC
E-peptide) drives proliferation and migration of satellite cells and
myoblasts, but at the expense of differentiation (Yang and Gold-
spink, 2002; Mills et al., 2007b; Philippou et al., 2009; Kandalla
et al., 2011).
Although much effort has focused on MGF/EB/hEC activity,
curiously few studies have explored the activity of the unique
human EB, and virtually no studies have examined EA. In some
ways EA would be expected to have a more substantial biologi-
cal function, because it is more highly expressed than the other
isoforms (Lowe et al., 1988), and because the sequence is highly
conserved in many species, whereas other splice forms diverge even
within primates (Wallis, 2009). This suggests that if any conserved
function can be ascribed to the E-peptides, the EA peptide is the
most likely candidate.
WHAT IS THE IDEAL FORM OF IGF-I FOR MUSCLE GROWTH:
WITH OR WITHOUT AN E-PEPTIDE?
With the ongoing dispute over E-peptide significance, we won-
dered if they were dispensable for IGF-I actions. In other words,
could IGF-I function in the absence of the E-peptide? Using viral
mediated gene transfer into mouse muscle, we expressed two
rodent IGF-I isoforms (IA and IB) as well as an IGF-I lacking
either E-peptide (mature IGF-I). Interestingly, both IA and IB
caused more hypertrophy compared to mature IGF-I only, imply-
ing that the E-peptide is necessary and important for proper
IGF-I secretion, IGF-IR activation, and/or downstream signal-
ing (Barton et al., 2010). These findings are consistent with the
phenotypes in two transgenic mouse models with muscle-specific
IGF-I expression. The first mouse model expressed IGF-IA,and the
mice exhibited robust skeletal muscle hypertrophy (Musaro et al.,
2001). However, a mouse expressing mature IGF-I only displayed
no hypertrophy (Shavlakadze et al., 2006). Together, these results
suggest E-peptides are required for IGF-I to cause hypertrophy, or
that their presence enhances IGF-I effects in muscle.
To understand how this enhancement might occur, we
expressed fluorescently tagged constructs in myoblast cell culture
to test E-peptide effects on IGF-I secretion and uptake (Pfeffer
et al., 2009). We found equivalent secretion of mature IGF-I,
pro-IGF-IA, and pro-IGF-IB, supporting that E-peptides were
not necessary for this process. However, E-peptides enhanced
the internalization of IGF-I, a step required for IGF-IR activa-
tion. Thus, IGF-I activity, including internalization and skele-
tal muscle hypertrophy, is improved in the presence of the
E-peptides.
E-PEPTIDE ACTIVITY: DEPENDENT OR INDEPENDENT OF
IGF-I?
Although the field has tried to document IGF-I independent
activity of the E-peptides, very early on it was proposed that
the E-peptides possessed IGF-I dependent activity, altering IGF-I
secretion, or its association with IGF binding proteins or the recep-
tors (Lowe et al., 1988; Goldspink, 1997). However, since the Igf1
gene encodes one E-peptide for every mature IGF-I, it is difficult
to discriminate IGF-I and E-peptide effects, especially in light of
the fact that most of the published functions of the E-peptides are
similar to IGF-I actions. Certainly, the most logical receptor for E-
peptides to modulate is IGF-IR. Alternatively, if the E-peptides do
have independent activity, they likely signal through their own E-
peptide receptor. Many studies have blocked IGF-IR with neutral-
izing antibodies, and demonstrate retention of hEB and synthetic
MGF activity for heightened proliferation and migration of differ-
ent cell lines (Siegfried et al., 1992;Yang and Goldspink, 2002; Mills
et al., 2007a,b; Philippou et al., 2009; Stavropoulou et al., 2009).
These results suggest that E-peptides have activity independent
of IGF-IR signaling. However, no E-peptide receptors have been
found, nor have any E-peptide binding partners been discovered.
While IGF-I independent activity may occur, it does not exclude
that IGF-I and the E-peptides could interact, converging on the
IGF-IR pathway. Evidence from our lab supports this possibility,
where E-peptides modulate IGF-I signaling and uptake (Barton,
2006b; Pfeffer et al., 2009). Further, the E-peptides stimulate the
same signaling pathways (MAPK) found downstream of IGF-IR
and many other receptors (Kuo and Chen, 2002; Philippou et al.,
2009; Stavropoulou et al., 2009). Additionally, E-peptide actions
on proliferation and differentiation resemble those of IGF-I itself
(Kandalla et al., 2011).
E-PEPTIDES AUGMENT IGF-I ACTIVITY
Recently, we have directly tested the effects of E-peptides on IGF-
IR signaling (Brisson and Barton, 2012) in order to clarify the
mechanisms underlying E-peptide activity. Counter to previous
studies, we found that both EA and EB increased ERK1/2 phos-
phorylation in myoblast culture, but not when IGF-IR is inhibited.
To determine if the E-peptides activate IGF-IR directly, we tested
if treatment of E-peptides alone, or in combination with IGF-I,
could induce IGF-IR phosphorylation. We found that the E-
peptides do not directly activate IGF-IR alone, but enhance the
ability of IGF-I to activate IGF-IR (Figures 2A–C). Further, when
myoblasts are treated with IGF-I and E-peptides, the E-peptides
increase phospho-ERK1/2, but not phospho-Akt. We propose that
E-peptides modulate IGF-IR signaling by enhancing the MAPK
pathway, but not the PI3K/Akt pathway, therefore tuning IGF-IR
downstream signaling.
Complementary to these results, we found that pro-IGF-I can
drive IGF-IR phosphorylation similarly, or to even a greater extent
than mature IGF-I (Figure 2D) (Durzynska et al., 2013a), sug-
gesting that IGF-I is more potent at receptor activation when still
attached to EA. Similar to simultaneous EA and IGF-I exposure
causing a ∼25% increase in receptor phosphorylation compared
to IGF-I alone (Figures 2A,C), when pro-IA and mature IGF-I
are compared in IGF-IR activation assays, pro-IA is 20–40% more
potent that mature IGF-I (Durzynska et al., 2013a). In contrast,
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FIGURE 2 | E-peptides affect IGF-IR signaling. (A) A Kinase Receptor
Activation Assay (KIRA) to specifically measure IGF-IR phosphorylation was
used. IGF-I at 2 nM was tested in addition to increasing amounts of
synthetic E-peptides. Both EA and EB showed a dose-dependent
augmentation of IGF-IR phosphorylation compared to IGF-I alone. Data
taken from Brisson and Barton (2012). (B) Normal conditions when IGF-I is
added to myoblasts, activating IGF-IR, and leading to increases in MAPK
and PI3K/Akt signaling. (C)When IGF-I is present, synthetic E-peptides
increase receptor activation and tune downstream signaling toward the
MAPK pathway. (D) Pro-IGF-I leads to more IGF-IR phosphorylation than
mature IGF-I alone, but the consequences on downstream signaling are
unknown. (E) E-peptide MAPK activation is inhibited via NVP AEW541, an
IGF-IR inhibitor. (F) E-peptide IGF-IR augmentation requires IGF-I.
glycosylation of pro-IGF-I appears to impair IGF-IR activation.
Structurally, the C-terminal E-peptide extension faces away from
the ligand binding site on IGF-IR, suggesting that it does not inter-
fere with mature IGF-I/IGF-IR association (Vajdos et al., 2001). In
fact, when a polyethylene glycol (PEG) group is attached to IGF-I
where the E-peptide would be, the large PEG group still allows IGF-
I/IGF-IR binding (Metzger et al., 2011). Although it is unclear if
PEG-IGF-I mimics pro-IGF-I or glycosylated-pro-IGF-I, we spec-
ulate that the small E-peptide protruding from IGF-I when it is
bound to IGF-IR can still have activity.
Unlike the previous studies showing IGF-I independent activ-
ity of the E-peptides, our current findings demonstrate a
requirement for IGF-I presence in E-peptide activity. First, in
myoblasts when the IGF-IR receptor kinase activity is inhib-
ited via pharmacologic inhibition (Figure 2E), the E-peptides
can no longer increase MAPK signaling, showing that E-peptide
MAPK stimulation is IGF-IR dependent. Second, when no IGF-
I is present, the E-peptides fail to increase receptor activation
(Figure 2F).
Can IGF-I dependent and independent activity of the E-
peptides co-exist? While our results counter the existence of
an IGF-I independent pathway for the E-peptides, we cannot
exclude the possibility. The experimental strategies employed dif-
fer across studies, including different cell lines, methods to increase
E-peptides, and reagents to examine IGF-IR dependence. For
instance, blockade of IGF-IR signaling by neutralizing antibodies
can lead to receptor internalization and degradation (Chow et al.,
1998; Hailey et al., 2002), and this may confound the interpretation
of E-peptide effects, since we know that E-peptides affect receptor
internalization and localization (Pfeffer et al., 2009; Brisson and
Barton, 2012).
New data from outside our lab support the idea that the E-
peptides modulate IGF-I activity, but through a different mech-
anism. The E-peptides contain a high percentage of basic amino
acids, and are thus highly charged. One group tested if the E-
peptides had an affinity for charged surfaces, and discovered that
the E-peptides could tether pro-IGF-I to the ECM. Hence, the
E-peptides can store IGF-I locally in tissues. The ECM tether-
ing modifies not only IGF-I location, but also its bioavailability
(Hede et al., 2012). This mechanism could explain why pro-IGF-I
enhances growth in vivo more than mature IGF-I (Barton et al.,
2010), but it cannot explain the E-peptides effect on IGF-IR acti-
vation, as those experiments were performed with free E-peptides
that were not attached to IGF-I. Consequently, the E-peptides may
be modulating IGF-I localization and activity through multiple
mechanisms.
FUTURE DIRECTIONS
Previous studies examining the activity of the E-peptides may
have attempted to eliminate IGF-IR activity, but no study to our
knowledge has tried to remove IGF-I itself, to directly test if the E-
peptides require IGF-I for activity. We have addressed this issue by
examining IGF-IR activation with and without exogenous IGF-
I. However, even in experiments where IGF-I is not specifically
added, there is likely IGF-I present in the cell media, as most cells
produce and secrete IGF-I. Thus, the E-peptides must be tested
in a truly “IGF-I-free” environment, to confirm that E-peptide
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activity is IGF-I dependent. Cells or mouse models that do not
express IGF-I could be used in future experiments to address this
issue.
The free E-peptides or the E-peptides included in pro-IGF-I
isoforms could affect the on/off rates of IGF-I/IGF-IR binding,
which in turn could affect receptor downstream signaling. In fact,
the result that MAPK is stimulated while PI3K/Akt is not after
E-peptide treatment suggests that the there is a change in the
kinetics of receptor-ligand interaction, which has a greater impact
on activation of the PI3K/Akt pathway than on the MAPK path-
way (Denley et al., 2005). The PI3K/Akt pathway is more sensitive
to changes in IGF-I/IGF-IR binding, and this could explain why
the E-peptides modulate IGF-IR, but favor MAPK to PI3K/Akt
signaling.
The largest unanswered question is how do the E-peptides aug-
ment IGF-IR activation? It could be that the E-peptides bind
to or recruit other proteins that can modulate tyrosine kinases.
Even though there is evidence in the literature that the E-peptides
do not bind to the same binding site as IGF-I (Siegfried et al.,
1992; Kuo and Chen, 2003), they could potentially still bind IGF-
IR, but not in the IGF-I binding pocket. This issue, as well as
whether or not the E-peptides have the same effects in vivo as they
do in myoblast cell culture, are further directions that must be
addressed.
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